Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) LATS1 Antibodies:
anti-Human LATS1 Antibodies:
anti-Rat (Rattus) LATS1 Antibodies:
Go to our pre-filtered search.
Human Polyclonal LATS1 Primary Antibody for IHC (p), WB - ABIN391033
Iida, Hirota, Morisaki, Marumoto, Hara, Kuninaka, Honda, Kosai, Kawasuji, Pallas, Saya: Tumor suppressor WARTS ensures genomic integrity by regulating both mitotic progression and G1 tetraploidy checkpoint function. in Oncogene 2004
Show all 6 Pubmed References
Human Polyclonal LATS1 Primary Antibody for IP, WB - ABIN4891893
Xiang, Gilkes, Hu, Takano, Luo, Lu, Bullen, Samanta, Liang, Semenza: Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. in Oncotarget 2015
Human Polyclonal LATS1 Primary Antibody for IF (p), IHC (p) - ABIN872292
Grijalva, Huizenga, Mueller, Rodriguez, Brazzo, Camargo, Sadri-Vakili, Vakili: Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration. in American journal of physiology. Gastrointestinal and liver physiology 2014
Thus AMOT (show AMOT Antibodies) is a direct substrate of Lats1/2 mediating functions of the Hippo pathway in endothelial cell migration and angiogenesis.
lats genes show distinctly different expression profiles during gastrulation. lats1 is almost ubiquitously expressed through development, and lats2 (show LATS2 Antibodies) is more prominently expressed in the non-neural ectoderm region of zebrafish gastrula.
Study demonstrates that, in 3 different murine syngeneic tumor models (B16, SCC7, and 4T1), loss of the Hippo pathway kinases LATS1/2 (large tumor suppressor 1 and 2) in tumor cells inhibits tumor growth; data indicate a new paradigm for how tumor immunogenicity is regulated through the Hippo signaling pathway in tumor cells.
Results showed that the Hippo pathway is active in ovarian follicles and that LATS1 is required to maintain the pool of germ cells and primordial follicles.
The control of LATS activation by angiotensin II and subsequent YAP (show YAP1 Antibodies) localization is important for podocyte homeostasis and survival.
Willin (show FRMD6 Antibodies) is predominantly expressed in fibroblasts and that Willin (show FRMD6 Antibodies) expression activates the Hippo signaling cascade
LATS1 tumor suppressor is a novel actin-binding protein and negative regulator of actin polymerization.
KIBRA (show WWC1 Antibodies) associates with and activates Lats (large tumor suppressor) 1 and 2 kinases by stimulating their phosphorylation on the hydrophobic motif
Lats1 enhances the activity of FOXl2 (show FOXL2 Antibodies) as a repressor of the StAr promoter. st
Overexpression of YAP2 (show YAP1 Antibodies) in cells promoted apoptosis, whereas the Mst2 (show STK3 Antibodies)/Lats1-induced phosphorylation of YAP (show YAP1 Antibodies) partially rescued the cells from apoptotic death.
Genome-wide location arrays in cell lines of various cell types revealed that Lats1 was a transcriptional target of CUX1 (show CUX1 Antibodies).
Low LATS1 expression is associated with breast cancer.
Loss of LATS1 expression is associated with pancreatic cancer.
TNFAIP8 (show TNFAIP8 Antibodies) regulates Hippo (MST1 (show MST1 Antibodies)/2) signaling through its interaction with LATS1.
Lats1 SUMOylation at K751 suppresses its kinase activity and subsequently attenuates its tumor-suppressor functions in HepG2 cells.
High LATS1 expression is associated with Colorectal Tumorigenesis and Metastasis.
A group of miRNAs have been demonstrated to directly target components of the Hippo signaling pathway, such as YAP (show YAP1 Antibodies), TAZ (show TAZ Antibodies) and LATS1/2 in oncogenesis. (Review)
findings reveal a non-canonical (that is, YAP (show YAP1 Antibodies)/TAZ (show TAZ Antibodies)-independent) effect of LATS in the regulation of human breast cell fate
AGO2 (show EIF2C2 Antibodies) immunoprecipitation revealed LATS1 as a novel proapoptotic target of miR (show MLXIP Antibodies)-21 in T cells.
LATS1 was downregulated in cervical cancer and may suppress cell growth and invasion through regulating the expression of cyclin E (show CCNE1 Antibodies), p27 (show PAK2 Antibodies), MMP9 (show MMP9 Antibodies) and YAP (show YAP1 Antibodies).
PARD3 (show PARD3 Antibodies) promotes interaction between PP1A (show PPP1CA Antibodies) and LATS1 to induce LATS1 dephosphorylation and inactivation,leading to dephosphorylation and activation of TAZ (show TAZ Antibodies)
The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments.
large tumor suppressor
, serine/threonine-protein kinase LATS1
, LATS homolog 1
, LATS, large tumor suppressor, homolog 1
, LATS, large tumor suppressor, homolog 1 (Drosophila)
, serine/threonine-protein kinase LATS1-like
, WARTS protein kinase
, large tumor suppressor homolog 1
, large tumor supressor, homolog 1
, LATS (large tumor suppressor, Drosophila) homolog 1
, large tumor suppressor 1